PLYGF (PolyPeptide Group AG) Cyclically Adjusted PS Ratio: (As of Jul. 08, 2026)


PLYGF PolyPeptide Group AG PLYGF
61 GF Score
Price $43.00
GF Value $40.58
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Cyclically Adjusted PS Ratio?

PolyPeptide Group AG does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


PolyPeptide Group AG  (OTCPK:PLYGF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


PolyPeptide Group AG Cyclically Adjusted PS Ratio Related Terms


PolyPeptide Group AG Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Cyclically Adjusted PS Ratio Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PLYGF vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Cyclically Adjusted PS Ratio falls into.


PLYGF
61GF Score
PolyPeptide Group AG PLYGF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

PolyPeptide Group AG does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $43.00 is trading 6% above its estimated GF Value™ of $40.58. GuruFocus considers PolyPeptide Group AG to be Fairly Valued.

Key valuation signals for PLYGF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $40.58 vs. price of $43.00 (6% above fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score

Get the complete analysis for PLYGF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.00
Price
$40.58
GF Value